Provided by Tiger Trade Technology Pte. Ltd.

Acrivon Therapeutics, Inc.

2.09
+0.03001.46%
Post-market: 2.05-0.0400-1.91%19:58 EDT
Volume:160.13K
Turnover:330.51K
Market Cap:89.45M
PE:-1.11
High:2.11
Open:2.04
Low:2.02
Close:2.06
52wk High:3.56
52wk Low:1.27
Shares:42.80M
Float Shares:25.69M
Volume Ratio:0.82
T/O Rate:0.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8800
EPS(LYR):-2.0151
ROE:-64.63%
ROA:-38.02%
PB:1.03
PE(LYR):-1.04

Loading ...

Acrivon Therapeutics Names Michaela Levin Chief Business Officer

Reuters
·
Yesterday

Acrivon Therapeutics Appoints Michaela Levin, Ph.d., as Chief Business Officer

THOMSON REUTERS
·
Yesterday

Press Release: Acrivon Therapeutics Appoints Michaela Levin, Ph.D., as Chief Business Officer

Dow Jones
·
Yesterday

Acrivon Therapeutics, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 13

Acrivon Therapeutics, Inc Q2 Income from Operations USD -18.668 Million

Reuters
·
Aug 13

Acrivon Therapeutics, Inc Q2 Basic EPS USD -0.43

THOMSON REUTERS
·
Aug 13

Press Release: Acrivon Reports Second Quarter 2026 Financial Results and Highlights Upcoming 2026 Clinical Data Catalysts

Dow Jones
·
Aug 13

Acrivon Therapeutics, Inc. Expected to Post a Loss of 50 Cents a Share - Earnings Preview

Reuters
·
Aug 08

Acrivon Advances ACR-2316 into Randomized Dose Expansion in Phase 1/2 Trial

Reuters
·
Aug 05

Acrivon Advances Acr-2316, a Potential First-in-Class Wee1/Pkmyt1 Inhibitor, into Randomized Dose Expansion in Its Ongoing Phase 1/2 Study

THOMSON REUTERS
·
Aug 05

Acrivon Therapeutics Announces Availability of New Press Release

Reuters
·
Jul 22

Will Acrivon Therapeutics (NASDAQ:ACRV) Spend Its Cash Wisely?

Simply Wall St.
·
Jul 11

Acrivon Therapeutics shareholders approve amended 2022 equity incentive plan

Reuters
·
Jun 18

Acrivon CEO joins TD Cowen Oncology Innovation Summit virtual fireside chat

Reuters
·
May 21

Pleasing Signs As A Number Of Insiders Buy Acrivon Therapeutics Stock

Simply Wall St.
·
May 19

Acrivon grants employee stock options for 111,150 shares under inducement plan

Reuters
·
May 16

Acrivon Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
May 16

Acrivon Therapeutics, Inc. (ACRV) Receives a Buy from Oppenheimer

TIPRANKS
·
May 14

Acrivon Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 14

Acrivon Therapeutics Q1 net loss narrows

Reuters
·
May 14